Biomarkers of immediate drug hypersensitivity

Abstract

Immediate drug hypersensitivity reactions (IDHRs) are a burden for patients and the health systems. This problem increases when taking into account that only a small proportion of patients initially labelled as allergic are finally confirmed after an allergological workup. The diverse nature of drugs involved will imply different interactions with the immunological system. Therefore, IDHRs can be produced by a wide array of mechanisms mediated by the drug interaction with specific antibodies or directly on effector target cells. These heterogeneous mechanisms imply an enhanced complexity for an accurate diagnosis and the identification of the phenotype and endotype at early stages of the reaction is of vital importance. Currently, several endophenotypic categories (type I IgE/non‐IgE, cytokine release, Mast‐related G‐protein coupled receptor X2 (MRGPRX2) or Cyclooxygenase‐1 (COX‐1) inhibition and their associated biomarkers have been proposed. A precise knowledge of endotypes will permit to discriminate patients within the same phenotype, which is crucial in order to personalise diagnosis, future treatment and prevention to improve the patient's quality of life.

Allergy to Beta-lactams: Myths, Realities and Novelties

“…This process generates the major antigenic determinant, benzylpenicilloyl (BPO), which constitutes approximately 95% of the antigenic profile of penicillins. 25 BPO, linked to a polylysine molecule, forms benzyl-penicilloyl-polylysine (PPL), a key component in routine ST commercially available by Diater® Spain.…”